Lentivirus infection

This early-stage trial tests three experimental mRNA vaccines designed to train the immune system to fight HIV. The study involves 96 healthy adults without HIV in South Africa. Researchers will check for side effects and measure whether the vaccines trigger specific immune cells…

This study tests Cervavac, an HPV vaccine, in women aged 15-25 who are living with HIV. HPV infection can lead to cervical cancer, and women with HIV are at higher risk. The trial compares two-dose and three-dose schedules of Cervavac against a standard vaccine to see how well th…

This early-phase trial tests a new HIV vaccine strategy in 36 healthy adults without HIV. The vaccine uses ferritin nanoparticles to display HIV envelope proteins, followed by an mRNA boost. The goal is to safely trigger broadly neutralizing antibodies that could protect against …

This early-phase trial is testing two experimental HIV vaccines in 52 healthy adults without HIV. The goal is to see if the vaccines are safe and can stimulate the immune system to produce broadly neutralizing antibodies, which are key to fighting many HIV strains. Participants r…

This early-stage study tests an experimental HIV vaccine in 35 people living with HIV. The goal is to see if the vaccine can safely trigger the body to produce VRC01-class antibodies, which are known to neutralize many HIV strains. Participants will temporarily pause their antire…

This early-stage study tests two experimental mRNA vaccines designed to teach the body to make powerful antibodies that can neutralize many types of HIV. About 53 healthy adults without HIV will receive the vaccines to check safety and immune response. The goal is to see if the v…

This early-stage trial is testing two experimental HIV vaccines, DV700P-RNA and DV701B1.1-RNA, for the first time in people. The study will enroll 45 healthy adults without HIV to check if the vaccines are safe and whether they trigger an immune response. Participants will receiv…

This early-stage trial tests whether three experimental mRNA vaccines can safely teach the immune system to recognize and fight HIV. About 108 healthy, HIV-negative adults aged 18-55 will receive one of the vaccines. The main goal is to check for side effects and see if the vacci…

This study tests whether extra COVID-19 vaccine doses are safe and work well for people with weakened immune systems, such as those with HIV, organ transplants, or blood cancers. Around 960 participants will receive different booster schedules to see which one boosts their protec…

This early-stage trial tests two experimental HIV vaccines, UVAX-1107 and UVAX-1197, in 25 healthy adults without HIV. The goal is to check if the vaccines are safe and whether they trigger an immune response. Participants will receive injections and be followed for about a year.

This study tests a new program to help people with HIV who also use substances stick to their HIV medications and stay in care. The program teaches coping skills and ways to manage substance use. Researchers want to see if the program is practical and acceptable to participants. …

This study tests whether a simpler two-drug pill (dolutegravir/lamivudine) works as well as a standard three-drug pill (bictegravir/emtricitabine/tenofovir alafenamide) for adults with HIV who have never been treated. About 473 participants will take one of the two pills daily fo…

This study tests if gabapentin, a medication for nerve pain, can help people with HIV who drink heavily achieve undetectable viral loads. About 220 participants will receive either gabapentin or a placebo for 3 months, along with counseling. The goal is to see if the drug improve…

This study compares three treatments for early HIV infection: zidovudine (AZT) alone, alpha-interferon alone, or both together. It aims to see which best lowers viral load, protects the immune system, and delays the first serious infection. About 180 adults with early HIV and hea…

This early-stage study tests a new lab-made antibody called VH4527079 in healthy adults and people with HIV. The goal is to check if it is safe and how the body processes it when given as a single shot or multiple infusions. About 102 participants aged 18-55 will take part. This …

This study tests whether personalized text messages can motivate people living with HIV in Vietnam to quit smoking. Participants receive motivational texts over six months and are encouraged to use a free government quitline that provides nicotine patches. The goal is to see if t…

This study tests whether delivering healthy food boxes, remote health monitoring, and one-on-one coaching can help low-income Black adults with type 2 diabetes better control their blood sugar. The trial enrolls 304 participants in the Deep South and tracks changes in HbA1c level…

This study tests a counseling program for people living with HIV who also face mental health challenges or substance use. The program uses one-on-one sessions to help with medication adherence, stress, and other life issues. Researchers will see if participants complete the progr…

This study tested whether monthly injections of two HIV drugs (cabotegravir and rilpivirine) work better than daily oral pills for people with HIV who have a history of missing doses. Over 450 participants were enrolled. The goal was to see if the long-acting shots reduce the cha…

This study looks at the safety and effectiveness of the HIV medication B/F/TAF in pregnant women who have had their virus under control for at least six months. About 50 women in their first trimester will continue taking the drug through pregnancy and 12 weeks after birth. Resea…

This early-stage study is testing the safety and how the body handles a new combination HIV drug (B/F/TAF) in full-term newborns who were exposed to HIV at birth. The goal is to see if this drug can be used to prevent the babies from getting infected. The study involves 16 infant…

This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…

This study tests a new HIV medicine, fostemsavir, in people whose HIV has become resistant to many other drugs. About 371 adults with multi-drug resistant HIV took part. The goal was to see if fostemsavir could lower the amount of virus in their blood. This is a disease control s…

This study tests whether switching to a new 2-drug combination pill (bictegravir/lenacapavir) is as safe and effective as staying on the standard 3-drug pill (Biktarvy) for people with HIV-1 whose virus is already suppressed. About 577 participants who have been on Biktarvy for a…

This study tests a 4-session behavioral program to reduce alcohol use in 450 people with TB and HIV in India. Unhealthy drinking can worsen TB and HIV outcomes. The program is added to usual care, and researchers will check if it lowers alcohol use and improves health. The goal i…

This study tests a mobile app called Connections for people living with HIV who also have substance use disorders. The app provides resources, weekly check-ins, discussion rooms, and private messaging with peer mentors and care teams. Researchers want to see if using the app help…

This study tests different ways to help people with HIV take their medication regularly. Researchers will enroll 534 people starting HIV treatment in Cape Town. They will use a device to track pill-taking and try different outreach methods, like calls or texts, to support adheren…

This pilot study in Malawi tests whether adding stigma-reduction counseling to standard depression treatment helps people living with HIV. Two hundred adults with HIV and depressive symptoms will receive counseling sessions that challenge myths and build coping skills. Researcher…

This study tests a program called Healthy Choices, which uses text messages and telehealth sessions to help young people with HIV (ages 18-29) in Florida manage their alcohol use and take their HIV medication every day. The goal is to improve daily medication adherence and viral …

This study is for adult women living with HIV who have experienced intimate partner violence. It tests a program that combines trauma-informed counseling with a safety planning app to improve mental health, HIV management, and safety. The goal is to see if this approach can reduc…

This study tests whether giving a guaranteed income of $6,750—either as a lump sum or monthly payments—helps people with HIV who have recently been in jail stay connected to care and keep the virus under control. Thirty-three participants will be randomly assigned to receive the …

This study tests whether a smoking cessation medication (varenicline) combined with tools to help people stick with treatment can improve quit rates for smokers living with HIV. About 340 participants will be followed for 6 months to see if they stop smoking, confirmed by breath …

This study tests whether two lab-made antibodies, 3BNC117-LS and 10-1074-LS, can safely reduce the hidden HIV reservoir in people already on suppressive antiretroviral therapy (ART). The trial involves 105 adults with HIV who will receive three infusions of the antibodies or a pl…

This study planned to test a blend of plant extracts and vitamin C, called Ahah, in people with HIV/AIDS. The goal was to see if it could protect and increase CD4+ T cells and B cells. However, the trial was withdrawn before enrolling any participants, so no results are available…

This early-phase trial tested whether combining two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), is safe and tolerable for people with advanced or hard-to-treat Kaposi sarcoma. The study enrolled 62 adults, including those wit…

This study gives children with HIV-1 who previously benefited from rilpivirine continued access to the drug along with other antiretrovirals. About 48 kids are taking part to monitor long-term safety and side effects. The goal is to keep their virus under control while checking f…

This study tests a new combination of two HIV drugs, bictegravir and lenacapavir, in children and adolescents aged 2 to 17 with HIV-1. The goal is to see if this once-daily pill is safe and works well enough to replace more complex daily medication routines. About 75 participants…

This study provides early access to the experimental drug TMC125 (etravirine) for HIV-1 patients who have failed multiple treatments and have few options left. Participants take TMC125 along with other antiretroviral drugs chosen by their doctor. The study tracks safety and how w…

This study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…

This Phase 2 trial tests whether a combination of dasatinib and quercetin (D+Q) can safely improve physical function in 82 older adults with HIV who are frail or prefrail. Participants take D+Q or a placebo in six 2-day cycles over 12 weeks, then are monitored for another 12 week…

This study looks at whether sending reminders (nudges) to doctors, patients, or both can increase the number of people with HIV who smoke getting help to quit. About 500 patients and their doctors are involved. The goal is to see if these nudges lead to more referrals and partici…

This Phase 2 trial tests whether adding Gammora® (a peptide) to standard antiretroviral therapy can reduce the hidden HIV reservoir in people newly diagnosed with HIV. Forty participants who have never taken HIV drugs will be randomly assigned to receive either Gammora® plus stan…

This early-stage study tests a single dose of a new long-acting antibody in 20 people with HIV who are not on regular medication. The goal is to see if the antibody is safe and can lower the amount of virus in the blood. Results will help design future studies for both HIV treatm…

This phase 3 trial tests whether a once-weekly pill (islatravir/lenacapavir) can keep HIV under control as well as daily standard care. About 600 people with HIV who already have undetectable virus levels will switch to the weekly pill or stay on their current daily regimen. The …

This study compares two methods of rolling out a program called Bridges, which gives financial literacy training and one-on-one mentors to 1,440 teens aged 11-17 who lost parents to AIDS in Uganda. The goal is to see which approach works better at reducing HIV risk and improving …

This study tests whether a combination of two antibodies (TMB-365 and TMB-380) given as an infusion every 8 weeks can keep HIV under control in people who are already suppressed on daily oral medication. About 88 adults with HIV will either switch to the antibody infusions or sta…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This study tests a mobile app called HealthMPowerment (HMP) designed to help young gay and bisexual men (ages 15-24) either start HIV prevention (PrEP) or stay on HIV treatment. About 1500 participants will get the app right away or after a delay. Researchers will see if the app …

This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…

This study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regul…

This study tests whether a combination of weekly video-counseling sessions and a mobile app can help young adults (18-29) living with HIV achieve viral suppression. Participants who are not virally suppressed will be randomly assigned to receive the intervention or standard care.…

This study is testing a mobile app called Suubi-Mhealth for Ugandan teens aged 14-17 who have both HIV and depression. The app uses cognitive-behavioral therapy (CBT) to help improve mood and make it easier to stick with HIV medication. About 248 teens will take part to see if th…

This study tests a program called Khanya, where trained peers (people with lived substance use experience) help HIV patients stick to their medication and reduce drug or alcohol use. The program is offered in steps: a basic version first, then a more intensive one if needed. Rese…

This study tests whether a telemedicine program that combines brief counseling with cognitive-behavioral therapy can help people with HIV reduce unhealthy alcohol use and improve their overall health. About 308 participants in Alabama will receive either the combined program or b…

This study tests whether offering small prizes (phone credit) can encourage young people aged 15-30 with HIV to take their medication every day. 560 participants in Uganda are split into groups with different reward rules. The goal is to see if these low-cost incentives improve a…

This study tests whether pomalidomide, a drug currently used for multiple myeloma, can help control HIV when people temporarily stop their standard antiretroviral therapy (ART). Thirty-two adults with well-controlled HIV will receive either pomalidomide or a placebo alongside low…

This study is testing a special kiosk placed in rural Appalachian Kentucky that provides clean syringes and harm reduction supplies to people who inject drugs. The goal is to see if the kiosk helps reduce the spread of HIV and hepatitis C, and lowers the risk of drug overdose. Ab…

This study tests whether semaglutide, a drug used for diabetes, can reduce harmful belly fat and improve heart health in people with HIV who have excess fat around the midsection (lipohypertrophy). About 108 participants will receive either semaglutide or a placebo for 32 weeks. …

This study looks at whether a trained friend, family member, or partner can safely give long-acting HIV injections at home. It involves 1,000 people with HIV who are already on the injectable treatment and have the virus under control. The goal is to make it easier for people to …

This study tests whether people with HIV who are already well-controlled on a daily pill (B/F/TAF) can safely switch to a once-weekly tablet (islatravir/lenacapavir). About 600 participants will take either the weekly pill or continue their daily regimen for 48 weeks. The goal is…

This study follows 500 people with HIV across Europe who are taking the medication doravirine. Researchers want to see how well the drug controls the virus over 12 months, how many people stop taking it, and if the virus becomes resistant. The study includes people new to treatme…

This study tests whether a combination of two lab-made antibodies and an antiviral drug called lenacapavir, given every 6 months, can keep HIV under control in adults whose virus is already suppressed by daily pills. About 83 participants will either switch to the new long-acting…

This study looks at how safe and effective certain HIV medicines are for children and teens (ages 4 weeks to under 18 years) who already have the virus under control. Participants take a combination of drugs (atazanavir or darunavir boosted with cobicistat, plus emtricitabine/ten…

This study is testing two mobile health tools—a computer-delivered program and motivational text messages—to help young adults (ages 18-24) in Zambia better manage their HIV and cut down on alcohol use. The goal is to see if these tools are easy to use and acceptable to participa…

This trial tests a video-based counseling program for adolescents living with HIV in Malawi. About 1,800 teens and their treatment supporters will either receive the video intervention or standard care. The goal is to see if the videos help teens take their medication regularly a…

This study tests whether a new once-weekly oral combination of two experimental drugs, lepetegravir and lenacapavir pacfosacil, can keep HIV under control as well as the daily pill Biktarvy. About 675 adults with already-suppressed HIV will take either the weekly combo or continu…

This study tests a program called PASEO that helps teenagers with HIV in Lima, Peru, successfully move from pediatric to adult HIV care. The program includes a helper who checks in monthly, peer support groups, education sessions, and mental health support. About 160 teens will t…

This early-phase study tests whether taking prebiotic fiber and probiotics can improve fatty liver disease in people with HIV. Researchers believe changes in gut bacteria may contribute to liver problems. The trial involves 63 participants and measures liver fat and gut health ma…

This pilot study tests whether giving the smoking-cessation drug varenicline to people with HIV who also have alcohol use disorder is practical and safe. Thirty participants will receive the medication along with support from a pharmacist and psychiatrist. The goal is to see if t…

This study looks at whether older adults (60+) living with HIV in Kenya can safely switch from their current three-drug pill to a simpler two-drug pill called DTG/3TC. About 240 participants who are already stable on treatment will be followed for 96 weeks. The main goal is to se…

This study tests whether two lab-made antibodies can safely control HIV in people who stop their regular antiretroviral therapy for a short time. Thirty-two adults in Sub-Saharan Africa who are currently on HIV treatment will receive either the antibodies or a placebo. The goal i…

This study tests a program where trained peers use motivational interviewing to encourage people who use drugs to check their drugs for dangerous substances and adopt safer use behaviors. The goal is to reduce fatal and non-fatal overdoses, as well as HIV and hepatitis C infectio…

This study compares a shortened steroid regimen (8 days for moderate, 14 days for severe pneumonia) against the standard 21-day course in 196 HIV patients with Pneumocystis pneumonia. The goal is to see if the shorter treatment is non-inferior in preventing death and complication…

This early-stage study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the hidden viral reservoir in people living with HIV. About 107 adults, either new to treatment or already on stable therapy,…

This study is testing the HIV medication Biktarvy (a combination of three drugs) in adolescents and children who have HIV-1. The goal is to see how the drug works in younger bodies, confirm the right dose, and check for side effects. About 177 participants will take the pill once…

This study looks at whether having a nurse case manager helps people with multidrug-resistant tuberculosis (MDR-TB) and HIV complete their long treatment. About 3,600 patients in South Africa are involved. Half of the clinics have a nurse case manager to guide care, while the oth…

This Phase 3 trial tests whether people with HIV who are already well-controlled on daily pills can switch to a monthly injection of two drugs (cabotegravir and rilpivirine) and stay just as healthy. About 630 adults whose virus is suppressed on a standard three-drug pill regimen…

This study tests a 'data-to-suppression' approach to help people with HIV who are not virally suppressed. It uses reports to guide support services for about 1,500 low-income individuals in New York City. The goal is to improve viral suppression rates and reduce health disparitie…

Severe acute malnutrition affects millions of children worldwide and often leads to death after hospital discharge. This phase 3 trial tests whether giving a combination of antibiotics (rifampicin, azithromycin, isoniazid, and vitamin B6) for several weeks can lower the risk of d…

This study tests a new medicine called lenacapavir in people with HIV whose current drugs are no longer working due to multidrug resistance. The drug is given as a pill and an injection, and is added to their failing regimen for 14 days before switching to an optimized background…

This study tests a new drug, VH3810109, given with another HIV medicine (cabotegravir) in adults whose HIV is already well-controlled. The goal is to see if this combination can keep the virus suppressed as well as standard treatments. About 185 participants will receive either t…

This study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…

This study tests whether virtual or in-person support helps teens with HIV stay in care and keep the virus under control. About 570 teens aged 15-19 in South Africa will receive either standard care or extra support to prepare for moving to adult clinics. The goal is to see which…

This study looks at whether giving long-acting HIV injections at home is as practical and acceptable as giving them in the hospital. About 120 adults with well-controlled HIV will receive the shots either at home or in the hospital. Researchers will measure how easy and appropria…

This study tests whether a two-drug combination (dolutegravir and lamivudine) is as safe and effective as the standard three-drug HIV treatment for children aged 2 to 15. About 386 children who already have undetectable HIV levels will take either the two-drug pill or their usual…

This study tests a new HIV medicine called fostemsavir in children and teens (ages 6-17) whose current HIV drugs are no longer working because the virus has become resistant. The goal is to see if the medicine is safe and can lower the amount of HIV in the blood when taken with o…

This study aimed to test a new solid tablet combining two HIV drugs (darunavir and ritonavir) for children aged 3 and older weighing 10-25 kg. The goal was to find the right dose and check safety and acceptability. However, the trial was withdrawn before any participants were enr…

This phase 1 trial tests a new therapeutic HIV vaccine (CH505 TF chTrimer) in 30 adults living with HIV who are on suppressive antiretroviral therapy. The vaccine is designed to stimulate the immune system to produce new antibodies against HIV. The study is currently suspended an…

This study tests whether baricitinib, a drug used for arthritis, can safely reduce the hidden HIV reservoirs in people who already have the virus under control with standard HIV medication. Thirty adults with HIV will take either baricitinib or a placebo daily for 12 weeks while …

This study looks at whether testing high-risk newborns for HIV right after birth using a point-of-care test can speed up diagnosis and treatment. Infants who test positive will start on a dolutegravir-based drug regimen. Researchers will track how quickly the virus becomes undete…

This early-phase trial tests whether a combination of two experimental vaccines, an immune booster, and two powerful antibodies can help people with HIV control the virus after stopping their daily antiretroviral therapy. Eleven participants will receive the regimen while on ART,…

This phase 2 trial tests whether a 12-week combination of four drugs (bedaquiline, clofazimine, pyrazinamide, and delamanid) works better than the standard 26-week treatment for drug-susceptible tuberculosis. About 94 adults with TB will be randomly assigned to either the short r…

This study looks at whether giving HIV treatment to babies within the first week of life can reduce the amount of virus hiding in their bodies. Researchers want to see if this early start helps the immune system fight HIV better, possibly allowing children to stop medication for …

This study tests whether giving people with HIV same-day results from a simple urine test and a viral load test can help them stick to their medication and keep the virus under control. About 539 people starting HIV treatment in South Africa will take part. The goal is to see if …

This study tests whether text messages and counseling can help women living with HIV make better decisions about contraception and pregnancy. About 3,310 women in Kenya will receive either standard care or the mobile health program. The goal is to reduce unplanned pregnancies and…

This study tests a pharmacist-led program to help women with HIV who also face social challenges like housing or food insecurity. The program supports switching from daily pills to a long-acting injectable medication (cabotegravir/rilpivirine) given every two months. The goal is …

This study tests if a once-weekly combination of two oral drugs, islatravir and lenacapavir, can keep HIV under control in people whose virus is already suppressed. 142 participants switched from their daily HIV pill to this weekly regimen. The main goal is to see if the virus st…

This study tests a smartphone app and a tablet dashboard for community health workers to support people with both tuberculosis (TB) and HIV in South Africa. The app helps patients stay on track with their medications, while the dashboard alerts health workers if someone needs ext…

This study tests whether doxycycline, an antibiotic, can slow the worsening of emphysema in people living with HIV. About 133 current or former smokers with HIV will take doxycycline for 72 weeks. Researchers will measure lung function, walking ability, and check for antibiotic r…

This study tests whether a drug called N-803 (IL-15) can train the immune system to control HIV without daily antiretroviral therapy. Twenty people with HIV on stable treatment will receive the drug or a placebo, then temporarily stop their HIV meds to see if the virus stays unde…

This was a planned phase 2 study to test a combination of two long-acting drugs, cabotegravir and lenacapavir, for people with HIV who have tried many treatments. The goal was to see if switching to these injections every two months could keep the virus under control. However, th…

This study tests whether combining urban gardening with peer nutritional counseling can improve HIV care outcomes for people who also face food insecurity. About 433 adults with HIV in the Dominican Republic who have trouble getting enough food will take part. The goal is to see …

This study tested whether giving HIV-positive teens in Uganda access to savings accounts, financial training, and mentorship helps them take their HIV medication regularly. 702 teens aged 10-16 from 40 clinics took part. The goal was to see if economic stability can improve treat…

This study looks at whether having a trained peer (someone with similar experiences) as a case manager can help people with HIV who also have mental health or substance use problems get the care they need. About 405 adults from an HIV clinic will be randomly assigned to either us…

This study tests four different support tools—financial literacy training, matched savings accounts, a cartoon-based adherence guide, and role models with HIV—to see which combination best helps youth aged 11-17 in Uganda stay on their HIV medication and keep the virus undetectab…

This study tests a program to help people living with HIV in Botswana stop smoking. It combines counseling with a medication called varenicline. The goal is to see if this approach helps them quit and improves their health. The study involves 750 participants who are daily smoker…

This study tests whether giving higher doses of a TB drug (rifampicin) plus an extra antibiotic (levofloxacin) for 14 days, with or without steroids, can help more people survive. It includes 732 adults with HIV who are hospitalized for TB that has spread beyond the lungs. The go…

This study looks at how well the drug ibalizumab works for people with multidrug-resistant HIV in everyday medical practice. It compares patients who receive ibalizumab plus other HIV drugs to similar patients who do not receive ibalizumab. The goal is to understand long-term vir…

This Phase 3 trial tests whether switching from daily HIV pills to monthly injections of cabotegravir and rilpivirine can keep the virus suppressed in adults with HIV. About 618 participants who are already virally suppressed will either stay on their current pills or switch to t…

This study tests a program for couples to help adolescent girls and young women (ages 15-24) living with HIV in Uganda stay engaged in their HIV care. The approach works with male partners to reduce heavy drinking and intimate partner violence, which often interfere with women ta…

This study is checking the long-term safety of a once-daily pill containing two HIV drugs (doravirine and islatravir) in 2,000 adults with HIV-1 who already took it in earlier studies. Participants will take the pill for up to 192 weeks. The goal is to see how many people have se…

This study is checking the long-term safety of a daily HIV medication called doravirine/islatravir (DOR/ISL) in 641 adults who have already been taking it. The pill combines two drugs to control HIV-1. Participants will take a lower dose (0.25 mg islatravir) for up to 96 weeks. T…

This study is testing two tuberculosis (TB) prevention treatments in pregnant women who also have HIV. The goal is to see if these treatments are safe and how they interact with the HIV medication dolutegravir. About 252 pregnant women will take either a daily TB drug for one mon…

This study tests whether a once-weekly combination of two drugs (rifapentine and isoniazid) can safely prevent tuberculosis in children and teens with HIV who are already taking the antiretroviral dolutegravir. About 92 participants aged 3 months to 17 years will receive the TB p…

This study tests a program that helps HIV-positive men who have sex with men build social support to stay in medical care. One hundred participants in St. Petersburg, Russia, will either get individual counseling or that plus group sessions to boost resilience and connect with su…

This study tests two drug combinations in 300 people with HIV who have gained weight or have high cholesterol. One part compares dapagliflozin (a diabetes drug) to a placebo for weight loss. The other compares a two-drug statin combo to a single statin for lowering cholesterol. T…

This early study tests whether giving gene therapy after standard chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds anti-HIV genes to the patient's own blood stem cells, aiming to help the body fight HIV. Only 3 participants were enroll…

This study tests whether switching to a once-daily pill containing doravirine and islatravir (DOR/ISL) works as well as staying on current HIV medications for people whose virus is already undetectable. About 550 adults with HIV-1 who have been on stable therapy for at least 3 mo…

This study tests if people with HIV whose virus is already well-controlled on a standard three-drug pill (BIC/FTC/TAF) can safely switch to a new two-drug pill (DOR/ISL) taken once daily. About 514 adults with suppressed HIV will be randomly assigned to either stay on their curre…

This early-stage study tests whether giving gene therapy after chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds special anti-HIV genes to the patient's own blood stem cells to help the body fight HIV. Ten participants will receive the …

This study tests a new once-daily pill (doravirine/islatravir) for adults with HIV who have never taken HIV medication before. About 537 participants will receive either the new pill or a standard combination pill to see how well they control the virus and if they cause side effe…

This study tests a new combination pill (islatravir + ulonivirine) taken just once a week to control HIV. Researchers want to see if it works as well as the daily medication Biktarvy in keeping the virus suppressed. The trial involves 150 adults whose HIV is already well-controll…

This study tests whether people with HIV who are already virally suppressed on complex treatment can safely switch to a simpler two-drug combination of bictegravir and lenacapavir. About 689 participants will be randomly assigned to either switch to the new drugs or stay on their…

This study tests whether giving HIV patients their own genetically modified stem cells is safe and feasible. The cells are changed to resist HIV, and patients receive a mild chemotherapy drug before infusion. The goal is to see if the modified cells can help control the virus, bu…

This study follows 11 people who previously received a gene therapy called Cal-1 for HIV. The goal is to watch for any delayed side effects over many years. Researchers will also check whether the modified cells are still present and active in the blood. It is a safety-only study…

This early-phase trial tests a combination of HIV GP160 protein and BCG vaccine (used for tuberculosis) in 20 HIV-positive people without AIDS symptoms. The goal is to see if the mix can activate the immune system to recognize and kill HIV. It is a small proof-of-concept study, n…

This study tests whether taking omega-3 supplements (fish oil) for 8 weeks during pregnancy can help HIV-positive women on antiretroviral therapy have healthier babies. Researchers will measure birth weight, length of pregnancy, and inflammation levels. 92 pregnant women will be …

This study aimed to see if a personalized RNA vaccine, a powerful antibody (10-1074), and a drug called romidepsin could help people with HIV stop their daily antiretroviral pills while keeping the virus under control. The trial planned to enroll 56 adults with well-controlled HI…

This study tests a program that combines digital health tools (like medication reminders and online consultations) with social support to help people with HIV who struggle to take their medication regularly. Researchers will enroll 210 participants in Taiwan and track changes in …

This early-stage trial tests the safety and tolerability of two experimental injectable drugs (capsid inhibitors) in 85 healthy adults. Participants receive a single dose or multiple doses of the drug or a placebo. The goal is to see if these drugs are safe enough to study furthe…

This early-stage study tests a new approach to HIV treatment. Researchers take a person's own T-cells, modify them to better recognize and attack HIV, and infuse them back. The main goal is to check safety in 12 stable HIV patients, while also seeing if the modified cells can hel…

This study looks at how well the Shingrix vaccine protects against shingles in people over 50 living with HIV, compared to healthy adults of the same age and gender. About 225 participants will receive two doses of the vaccine and be monitored for one year. The goal is to see if …

This study compares different HPV tests to find the best way to screen for cervical cancer in women living with HIV in Latin America. Over 1,000 participants will provide cervical, vaginal, and urine samples, plus undergo colposcopy and biopsies. The goal is to identify which tes…

This study looks at different methods to find early signs of cervical cancer in women living with HIV in the Dominican Republic. The goal is to see which screening approach works best to catch abnormal cells caused by HPV. About 619 women aged 25-49 will take part, helping doctor…

This study looks at which tests work best to find early signs of HPV-related cancer in the cervix or anus of people living with HIV. About 1,586 participants from Mexico and Puerto Rico will be tested using different methods, including HPV tests and cell samples. The goal is to c…

This study tests a 24-week program called CoMPASS that uses rewards (contingency management) and extra support to help people who inject drugs take PrEP consistently for HIV prevention. About 526 participants with opioid use disorder will be enrolled. Those who don't stick with P…

This study looks at how to keep a youth-friendly HIV self-testing program called 4YBY running in Nigeria. It will involve over 1,200 young people aged 14-24 who are at risk for HIV. Researchers will compare standard program delivery with an enhanced version that includes extra su…

This study tests two counseling programs to help women who use drugs in Tanzania start and stay on PrEP, an HIV prevention pill. 200 women will be randomly assigned to receive either brief motivational counseling, the same plus extra mental health support, or standard information…

This study tests a new shot called lenacapavir, given once a year, to see if it can safely prevent HIV in people at risk. About 350 participants will receive the injection and be monitored for side effects and drug levels. If successful, this could offer a much more convenient op…

This study tests a program called ZAIMARA that brings together adolescent girls (ages 15-19) and their mother figures for a two-day workshop. The goal is to improve communication about HIV, sexually transmitted infections, and PrEP, and to increase HIV testing and prevention. Res…

This study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat c…

This study tests whether providing HIV prevention (PrEP) and hepatitis C treatment together at one location works better than sending patients to separate clinics. About 446 people who inject drugs will be randomly assigned to either on-site integrated care or off-site referrals …

This study tests a new option for preventing HIV: a shot given under the skin every 6 months, called lenacapavir. It compares how well people stick with the shot versus taking a daily pill (Truvada). About 268 people at higher risk for HIV will take part. The goal is to see if th…

This study is testing a web-based platform called Jom-TestPlus that lets transgender women in Malaysia order HIV self-test kits online and get real-time counseling. The goal is to help them quickly connect to HIV prevention or treatment services. Fifty participants will use the p…

This study is testing a web-based platform called Jom-TestPlus for men who have sex with men in Malaysia. The platform offers HIV self-testing, real-time online counseling, and help connecting to prevention or treatment services. Researchers want to see if this approach increases…

This study adapts an existing HIV prevention program, Many Men Many Voices, into a version called LAFIYA for young sexual minority men living in slums in Ghana. The goal is to reduce stigma and increase the use of HIV self-testing kits. Researchers will test whether the program i…

This study is testing a mobile-friendly app called DASH that provides information and guidance about PrEP (a daily pill that prevents HIV) to people who have used an HIV self-test kit. The app helps users explore their values and make informed decisions about starting PrEP, with …

This study tests whether trained peer navigators, connecting with students through a mobile health app, can increase the use of HIV prevention pills (PrEP) and contraception among sexually active female university students aged 18-24 in Zambia. 324 participants will be randomly a…

This study looks at better ways to find and prevent tuberculosis (TB) in people living with HIV. Researchers will test a new screening method and offer patients a choice of TB preventive medicines with extra support like text reminders. The goal is to improve TB detection and hel…

This study tests whether offering lottery-based rewards for saving money can help Kenyan men reduce behaviors that raise their risk for HIV and other STIs. About 1,500 men aged 18-39 who drink alcohol and have paid for sex in the past will be split into two groups. One group gets…

This study is testing whether the MVA-BN mpox vaccine is safe and triggers a strong immune response in 600 adults living with HIV in Kinshasa, DRC. Participants receive two vaccine doses 28 days apart and are grouped by their CD4 count. The goal is to see if the vaccine works wel…

This study tests a program to help HIV-positive adults get the HPV vaccine, which can prevent HPV-related cancers. The program gives clinics and staff tools to encourage vaccination. Researchers will track how many people start and finish the vaccine series over two years.

This study tests whether nurse-navigators can help adolescent girls and young women in Kenya start and continue taking PrEP, a daily medication that prevents HIV. About 1,900 participants will get PrEP at local pharmacies after buying birth control, and half will also receive ext…

This study tests whether offering HIV prevention medication (PrEP) through telehealth visits at local health departments helps more people who inject drugs start and stay on PrEP compared to standard education and referrals. Eighty participants in rural Appalachia will be randoml…

This study tests different support strategies to help people who inject drugs in rural areas start and continue taking PrEP, a daily pill that prevents HIV. About 424 participants from three syringe service programs will be randomly assigned to receive either peer-led counseling …

This phase 3 study tested a daily pill called F/TAF (Descovy) to prevent HIV infection in nearly 5,400 men and transgender women who have sex with men and are at high risk. Participants took either F/TAF or the existing prevention drug Truvada. The goal was to see if F/TAF is as …

This study tests a personalized support program (C4) to help Black men who have sex with men take their HIV prevention medication (PrEP) consistently. About 350 men will either get the program or standard care. The program addresses personal needs like mental health and housing t…

This study tests whether adding trauma-coping lessons to a relationship skills program helps teens aged 13-19 in Miami avoid unprotected sex and pregnancy. Nearly 1,000 youth will be split into three groups: one gets the combined program, one gets relationship skills only, and a …

This study works with primary care and reproductive health clinics to make it easier for women who inject drugs to get PrEP, a daily pill that prevents HIV. Researchers are testing a program where clinic staff get extra training and support to identify and prescribe PrEP to these…

This study tests a program called Tu'Washindi, designed by and for young women in Kenya. It combines support clubs and community sessions to help girls ages 15-24 reduce intimate partner violence and consistently use HIV prevention pills (PrEP). About 1,562 participants will be f…

This study tests whether giving a long-acting HIV prevention shot (lenacapavir) in community pharmacies is practical and acceptable. Seventy-five HIV-negative adults will receive the injection either twice a year or every three months, and researchers will track how many stay on …

This study tests whether a mobile app called LifeSkills can lower the number of new HIV infections among young transgender women aged 16-29 in the U.S. About 5,100 participants will use either the app or standard care, and their HIV status will be checked over time. The goal is t…

This study compares two low-burden strategies to increase HIV PrEP use among emergency department patients seeking care for sexual health issues. One strategy involves follow-up outreach after the visit, while the other offers a tele-sexual health visit during the ER stay. The go…

This study tested two ways to prevent HIV in over 5,000 adolescent girls and young women at risk. One group received a long-acting shot every six months, while others took daily pills. The goal was to see how well each method works to keep participants HIV-free.

This study tests whether sending HIV self-test kits to men who have sex with men on a subscription basis encourages them to test more regularly. 240 participants in Hong Kong will receive reminders to test during a control period, then receive actual test kits during an intervent…

This study tests a community-based approach to lower HIV rates among men who have sex with men (MSM) at highest risk in the southern United States. The strategy uses local coalitions to reduce barriers, promote testing, increase PrEP use, and improve care for those living with HI…

This study is testing a computer-based program called MES-PrEP to help young transgender women in Thailand start and stick with HIV pre-exposure prophylaxis (PrEP). The program provides personalized feedback and information based on each person's confidence and motivation. Resear…

This study tests whether trained peer educators can help more college students learn about and start taking PrEP, a daily pill that prevents HIV. About 123 students aged 18-26 from four HBCUs will take part. The goal is to see if this approach increases PrEP awareness and use ove…

This study looks at whether long-acting HIV prevention shots (CAB-LA) are safe and work well for breastfeeding mothers after childbirth. About 500 new mothers in Botswana will get the shots and be followed for 24 months along with their babies. The goal is to see if this method c…

This study looks at a new way to prevent HIV in people who inject drugs. It tests a shot given under the skin every 6 months (lenacapavir) and compares it to daily pills. The goal is to see how well the shot works in the body and if it is safe. About 181 people in the US are taki…

This study tests a 45-60 minute online program called PATHS that teaches parents how to talk to their gay or bisexual sons about sexual health. About 393 parent-teen pairs join, with teens aged 14-19. The goal is to see if the program improves teens' condom use, PrEP awareness, a…

This study is testing a package of tools—training for healthcare workers, quality improvement methods, and a community of practice—to help clinics in Kenya offer HIV prevention pills (PrEP) to pregnant and postpartum women. The goal is to screen more women and start them on PrEP …

This study is creating a women-centered HIV prevention program for young women aged 18-35 in Ghana. The program uses WhatsApp and community workshops to provide information on HIV self-testing and PrEP, aiming to reduce stigma and increase prevention uptake. Researchers will test…

This study tests whether collecting sexual health information electronically during routine gynecologic visits can increase the use of PrEP, a medication that prevents HIV. About 1,170 women aged 15-65 who are not living with HIV will participate. The goal is to see if this appro…

This study compares two ways to provide HIV prevention pills (PrEP) to young people in South Africa: the usual clinic-based approach versus a community-based model where pills are delivered and monitored outside clinics. Researchers will enroll 2,500 participants aged 16-30 to se…

This study tests whether a single dose of the HPV vaccine (Gardasil 9) can prevent persistent HPV infection in women living with HIV who have already been vaccinated. About 778 women will receive either the HPV vaccine or a meningitis vaccine (placebo) and be monitored for safety…

This study aims to see if mobile phone messages can help teens in Uganda prevent HIV and address related issues like mental health and alcohol use. Researchers will adapt an existing text and voice system to include HIV prevention info and mental health screening. About 200 adole…

This study looks at how to best help HIV clinics in Vietnam offer a short alcohol counseling program to patients who drink heavily. The goal is to reduce risky drinking and lower the chance of spreading HIV. Over 3,200 people living with HIV and clinic staff are taking part to se…

This phase 3 trial tests lenacapavir, a long-acting drug given as a shot every six months, to prevent HIV infection. Over 3,200 participants at risk for HIV received either lenacapavir or daily pills. The goal is to see if the shot is as effective as daily PrEP, offering a more c…

This study tests a program called TIARAS, which combines a reward system for staying drug-free and on PrEP (HIV prevention pills or shots) with expressive writing about past trauma. The goal is to see if this approach lowers HIV risk in women who inject drugs. 219 women from Phil…

This study tests whether a brief alcohol intervention (a few counseling sessions) helps people who are starting or restarting PrEP (HIV prevention pills) to drink less and stick with their PrEP routine. About 562 participants in Hanoi will be randomly assigned to receive the inte…

This study tests whether adding a communication skills video and a substance use module to standard couples HIV testing can help male couples reduce drug use and risky sex. About 484 male couples are randomly assigned to receive standard testing alone or with one or both extra mo…

This study tests whether taking two TB prevention drugs daily for one month works as well as taking them weekly for three months. It includes 1,000 people with HIV or those living with someone recently diagnosed with TB. The goal is to see which schedule more people complete and …

This study tests a new version of the HIV prevention drug cabotegravir given as a shot every 4 months. About 229 teens and adults at risk for HIV will receive the injection to see how well the drug stays in the body and if it is safe. The goal is to make HIV prevention easier by …

This study follows 100 cisgender women in the southern U.S. who are already prescribed long-acting cabotegravir injections (Apretude) for HIV prevention. Over two years, researchers will track how many women stick with the shots, how satisfied they are, and rates of other sexuall…

This study tests a program to help pregnant and breastfeeding women in South Africa take a daily pill called PrEP that prevents HIV. The program includes extra counseling and community delivery of the pills for those who struggle to take them regularly. The goal is to see if this…

This study tests a mobile app called Combine to help gay, bisexual, and other men who have sex with men in rural southern US get tested for HIV and STIs and start taking PrEP (a daily pill that prevents HIV). About 473 men will use the app and be placed into one of four groups: s…

This study tests whether text reminders, commitment pledges, and planning prompts can help men who have sex with men stay on PrEP, a daily pill that prevents HIV. About 106 men in South Africa who are just starting PrEP will either get standard care or these extra nudges. The goa…

This large phase 3 study tests whether a long-acting injectable drug called cabotegravir, given every 2 months, is safe and effective for preventing HIV in women. Over 3,200 HIV-negative women are taking part, comparing the shot to daily oral Truvada. The goal is to see if the in…

This study tests whether a smartphone game called Tumaini can help prevent HIV among 1000 adolescents aged 12-14 in Kenya. The game teaches sexual health, risk reduction, and condom use through role-playing. Researchers will compare outcomes like age at first sex and condom use b…

This early-stage study tests a group healthcare model called Centering PrEP+ (C-PrEP+) to help sex workers take and stick with PrEP, a daily pill that prevents HIV. Instead of one-on-one visits, small groups meet with providers for health checks and interactive learning. The stud…

This study tests a new long-acting injection called lenacapavir, given every 6 months, to prevent HIV in cisgender women in the US. About 253 women will receive either the injection or daily pills (Truvada) to compare how well the drug works in the body, its safety, and how accep…

This study tests a program called PRISM that teaches teens with HIV how to manage stress, set goals, and build resilience. It involves three one-on-one sessions with a nurse. The goal is to see if the program is feasible and acceptable, and whether it reduces psychological distre…

This study compares two types of talk therapy—Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT)—for HIV/AIDS patients experiencing psychological distress. 72 adults on antiretroviral therapy will receive 8 weekly sessions of either therapy or standard…

This study looks at whether a program that combines physical activity with support from a peer is acceptable and practical for women living with both HIV and high blood pressure. About 50 women aged 40 and older will take part. The goal is to see if women stick with the program a…

This study tests ORCHID, an online skills-building program designed to improve mental health and reduce the risk of dropping out of care for aging women with HIV who also have HPV. The program includes 8 online sessions and optional meetings with a navigator. The study aims to se…

This study tests whether a mobile app-based nutritional program can help people living with HIV and fatty liver disease lose at least 5% of their body weight in 6 months. Participants are randomly assigned to use the app or receive standard lifestyle advice. The goal is to find a…

This study tests whether a home-based physical activity program, using a Fitbit and coaching sessions, can help people with HIV who drink heavily increase their daily steps and reduce their alcohol intake. The trial involves 222 participants in the U.S. who are low-active and dri…

This study tests whether offering chances to win prizes for completing job-search activities helps unemployed people with HIV/AIDS find work. 144 participants will be randomly assigned to either standard employment services or the same services plus prize-based rewards for 16 wee…

This study tests whether a home-based walking program can improve blood sugar, cholesterol, and body measurements in people living with HIV who also have metabolic syndrome. Fifty participants will gradually increase their walking over six months. The main goal is to see if the p…

This study tests whether a 48-week exercise program can improve physical function and reduce disability in HIV-positive adults over 50 in Côte d'Ivoire. 180 participants will be split into three groups: supervised group exercise, home-based exercise with phone support, or health …

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…

This study looks at HIV-infected adults who have been on antiretroviral therapy for a long time and have very low virus levels. Researchers want to see if the virus stays stable or changes over time. Participants visit the clinic every six months for blood tests and a special whi…

This study examines a program in two Boston-area jails designed to make HIV testing and treatment easier for people with opioid use disorder. Researchers will follow about 59 participants who are leaving jail within a month to see if they use HIV services, get tested, or take PrE…

This study tests whether a virtual training and peer-mentoring program called Project ECHO can help healthcare providers in Ethiopia improve cervical cancer screening and treatment for women living with HIV. The program focuses on using HPV self-sampling, a simpler screening meth…

This study looks at how HIV infection and aging impact the body's response to the Prevnar 13 vaccine, which protects against pneumococcal bacteria. Researchers will measure antibody levels in the lungs, nasal passages, and blood of participants aged 21-45 or 55-75, comparing thos…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…

This observational study follows 168 women living with HIV in Zimbabwe who have been treated for cervical pre-cancer. Researchers want to learn how often the disease comes back and whether HPV or DNA tests can predict recurrence. Participants will be monitored every six months fo…

This study looks at whether a rapid HIV antibody test can detect when the virus rebounds in people taking antiretroviral therapy (ART). Researchers will analyze stored blood samples from 6100 HIV-positive individuals in the US and sub-Saharan Africa. They will compare antibody le…

This study looks at HIV patients over 40 (or those on HIV therapy for over 10 years) who switched to either a three-drug or a two-drug antiretroviral regimen. Researchers will measure markers of inflammation in the blood and track how many patients develop other health conditions…

This study tests a strategy called EMPOWER that uses patient portals to send women educational materials about PrEP (medication that prevents HIV) and lets them easily schedule a doctor visit if interested. The goal is to see if this approach improves women's knowledge about PrEP…

This study tests a new digital tool called INCLUDE, designed to help clinics in Nepal identify and reduce stigma faced by people living with HIV. The tool includes a stigma assessment, a dashboard linking stigma to care data, and a library of stigma-reduction activities. Research…

This study was designed to see if the drug raltegravir could reduce hidden HIV in immune cells (lymphocytes and monocytes) in people with HIV who already had undetectable virus levels. It planned to enroll adults aged 18-60 with well-controlled HIV. However, the study was withdra…

This study checks if some people with HIV might be cured. Ten patients who have had undetectable HIV for at least 6 months will stop their antiretroviral therapy under close medical supervision. Doctors will watch for the virus to come back. The goal is to see if the infection is…

This study planned to test a program called Lafiya (meaning 'Wellness') designed to reduce stigma and discrimination faced by young gay, bisexual, and other men who have sex with men living in Ghanaian slums. The goal was to see if the program could increase HIV testing, use of P…

This study tests a program where veteran peer workers provide education, healthcare navigation, and social support to 150 veterans with opioid use disorder who are not connected to VA healthcare. The goal is to reduce risky behaviors related to overdose and HIV/HCV infection. Res…

This study adapts an existing stigma-reduction program specifically for pregnant and postpartum women living with HIV in Ghana. Researchers will interview 30 women and 20 providers to understand their experiences, then work with stakeholders to tailor the program. Finally, 90 pre…

This pilot study aimed to see if a home viral load test (TASSO device) is accurate and easy to use for people starting HIV treatment or trying to lower a high viral load. Participants would have collected samples at home and in the clinic. However, the study was withdrawn before …

This study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…

This study looks at whether a combination of two anti-HIV antibodies can keep the virus under control after people stop their daily HIV medications. Researchers will compare people who received the antibodies in a previous study to those who got a placebo. Participants will pause…

This study tracks 2,500 people with HIV in Brazil who are taking a common first-line treatment (tenofovir/lamivudine and dolutegravir) to see why some develop drug resistance. Researchers will test blood samples from those whose viral load remains detectable to look for resistanc…

This study aimed to see if personalized computer-based brain exercises could improve thinking skills in adults with HIV who have mild memory or attention problems. Researchers planned to enroll 120 people aged 40 and older, giving half of them training focused on their weakest me…

This study follows 298 older adults with HIV in Zambia to compare brain health between those who have had HIV for a long time (7+ years) and those with a shorter infection (1-2 years). Researchers will track memory, thinking, mental health, frailty, and nerve health over 6 years.…

This study looks at blood samples from 400 people with and without HIV to understand how aging and HIV infection change the body's immune response to the flu vaccine. Researchers will measure antibody levels and immune cell types to see who responds well to the vaccine and who do…

This study looks at how well the HPV vaccine works in women living with HIV and whether self-collected HPV tests can improve cervical cancer screening. About 650 women will use a self-swab kit at home or in the clinic. Those with positive results will get follow-up exams. The goa…

This study tests whether AI-powered X-ray analysis and portable molecular tests can help find tuberculosis (TB) and COVID-19 cases in African communities where many cases go undetected. Over 26,000 adults will be screened using these tools, and researchers will measure how quickl…

This study planned to see if faster testing and treatment for hepatitis C could be given to inmates right when they enter prison. The goal was to start medication sooner to reduce the spread of the virus. However, the study was withdrawn and no one took part.

This study is collecting blood samples and health information from 1,613 HIV patients to learn more about the infection and how to improve care. Researchers will track heart and brain health, as well as other medical conditions. The goal is to use this knowledge to make HIV treat…

This study looks at 40 people with HIV to see if a common drug, tenofovir, causes more immune system activation and helps the virus hide better in the body. Participants are already on stable HIV treatment and will provide blood and gut samples. The goal is to find ways to reduce…

This study was designed to test a new system that uses tiny silica particles on HIV medication (Biktarvy) and a smartphone app to help people track whether they have taken their pills. The goal was to see if the system is easy to use and accurate over 90 days. However, the study …

This study tests a program called LIFT to help people who inject drugs in Kyrgyzstan face less stigma and lower their risk of HIV. About 80 participants will join peer-led group sessions to build support and learn how to use HIV prevention services. The goal is to see if the prog…

This study tests whether a WhatsApp chatbot can improve HIV knowledge in 314 adults recently diagnosed with HIV in Nigeria. Participants use the chatbot for information, reminders, and questions, while a control group receives standard care. The study also looks at effects on res…

This study looks at how well a long-acting HIV injection (CAB+RPV LA) works for people who live far from their doctor. About 55 patients and clinic staff will share their experiences through surveys and interviews over 15 months. The goal is to understand what helps or hinders ge…

This study looks at medical records and follow-up data from 10 people living with HIV in four cities in southern Sichuan, China. The goal is to see how well HIV treatment is working by checking virus levels after 12 months. This is an observational study that does not test a new …

This study tests a program called ENHANCE-TTS that trains pharmacists at HIV clinics to provide tobacco treatment. Researchers will see if the program helps pharmacists offer more smoking cessation services and if it helps patients quit. About 172 people from six clinics will tak…

This study looks at how opioid use affects the immune system's response to the flu vaccine in people with and without HIV. Researchers will analyze blood samples from 400 participants to measure antibody levels and immune cell activity. The goal is to understand why opioid users …

This study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…

This study tests a new program to make it easier for people living with HIV to get screened for substance use disorders. The program uses online patient portals and in-clinic tools to find those who need help and connect them to treatment. Researchers will track how many people g…

This study tests a program to help caregivers tell children (ages 7-18) their HIV status in a supportive way. It involves 747 children and their caregivers across 12 clinics in Ghana. The goal is to see if this approach improves medication adherence and overall health.

This study looks at how HIV might disrupt the body's internal clock, which could lead to health problems like diabetes and heart disease. Researchers will track gene activity at different times of day in 80 people with and without HIV. The goal is to understand why these issues a…

This study aimed to understand how patients and clinic staff feel about using long-acting injectable medications to treat both HIV and opioid use disorder together. Researchers planned to enroll 30 patients and 5-10 staff, giving patients the combined injections and following up …

This small, early study is testing whether spironolactone, a drug already approved for high blood pressure, can reduce the hidden HIV reservoir in people on effective HIV treatment. Researchers will give the drug to 12 adults (both with and without HIV) to see how it affects a ke…

This study aimed to see if adding patient questionnaires, staff training, and telemedicine could improve mental health and substance use disorder care for people living with HIV. It was planned for five clinics in Alabama, but the trial was withdrawn before enrolling any particip…

This study follows 127 people with HIV-related Kaposi sarcoma in Malawi and South Africa who are receiving standard chemotherapy (paclitaxel or bleomycin plus vincristine). Researchers want to understand why some patients respond better than others, looking at factors like gender…

This study tests a computer program that predicts which HIV patients are most likely to need emergency care in the next two weeks. Care managers use this list to reach out and offer support, compared to usual care where they rely on schedules and judgment. The goal is to see if t…

This study observes over 15,000 HIV patients in Malawi to see how different ways of delivering HIV treatment (like group visits or community pick-up points) affect viral suppression, patient satisfaction, and clinic efficiency. Researchers surveyed patients and providers at 12 he…

This study looks at how often fatty liver disease occurs in people living with HIV. Researchers will measure liver fat in 1,250 adults with HIV who are on stable treatment. The goal is to understand the true scale of this liver condition in this group, which has been largely over…

This study follows 400 adults with HIV to learn how nonalcoholic fatty liver disease (NAFLD) develops and progresses in this group. Researchers will use a non-invasive scan to measure liver stiffness and fat content over one year. The goal is to fill major knowledge gaps, since p…

This study tests whether machine learning can predict which HIV patients are likely to miss clinic visits or have treatment failure. Researchers will give clinic workers risk alerts to help them reach out to high-risk patients. The goal is to improve retention in care and viral s…

This study surveys 771 adults with HIV in Zambia who have started or restarted antiretroviral therapy (ART) within the last six months. Researchers want to learn what services and support patients prefer during this critical early period, when many drop out of care. The goal is t…

This study looks at different ways to deliver HIV treatment in Zambia to see which methods work best for patients and clinics. Researchers will survey over 8,000 patients and healthcare providers at 12 health facilities. The goal is to help policymakers make better decisions abou…

This observational study is tracking over 15,500 people with HIV at 24 healthcare facilities in South Africa. Researchers are comparing different ways of delivering HIV treatment and care to see which models work best for patients and healthcare providers. The study looks at vira…

This study surveys about 1,100 adults in South Africa who have recently started or restarted HIV treatment. The goal is to understand what services and support they need to stay in care during the first six months, a time when many patients drop out. Results will help design bett…

This study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…

This pilot study is testing a new tool called PATH that helps doctors assess the unique health needs of people aged 50 and older living with HIV. Participants will answer questions about their health through a patient portal or with a research coordinator before a routine HIV app…

This study looks at two different methods to help VA clinics adopt a team-based depression care service for veterans living with HIV. The service has been shown to work well and save money, but no VA clinics currently use it. Researchers will compare the two approaches to see whi…

This pilot study looks at whether a computer-based alcohol intervention, combined with help from a community health worker, can reduce heavy drinking and improve HIV prevention among women. About 12 women who drink heavily and are either living with HIV or at risk for it will tak…

This study involves 65 healthy adults without HIV to see how well they tolerate two long-acting injections (cabotegravir and lenacapavir). Participants will receive both shots at different times and report on pain, bother, and overall satisfaction. The goal is to understand injec…

This study uses a special imaging scan (PET/CT) and a radioactive tracer to measure inflammation in the brain. Researchers will compare four groups: people with HIV and opioid use disorder, people with only one of these conditions, and healthy volunteers. The goal is to understan…

This study involves 48 adults with HIV who have had undetectable virus levels for at least 2 years while on antiretroviral therapy. Researchers are measuring two specific markers (CD32a and X) on immune cells to see if they relate to the amount of hidden HIV DNA in the body. The …

This study tests a program called CHIMES designed to help young Black gay and bisexual men living with HIV get better mental health care. The program includes posters, provider training, mental health screening, and case management. Researchers will track whether it leads to more…

This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…

This study looks at whether giving staff bonuses for hitting targets helps them deliver better substance use counseling to people with HIV. Researchers are comparing two strategies: one with just training and feedback, and another that adds monetary incentives. The goal is to see…

This study looks at how cannabis (specifically the drug Dronabinol) changes the immune system and genes in people with HIV. Researchers will take blood samples before and after giving Dronabinol to 160 participants. The goal is to understand these changes better, which could help…

This study looks at how well the mpox vaccine works and how safe it is in people with HIV compared to those without HIV. About 174 adults who either recently got the mpox vaccine or had a recent mpox infection will take part. The goal is to fill important knowledge gaps and help …

This study looks at how cannabis (marijuana) affects the levels of HIV medications in the blood and brain, as well as mood and thinking. Researchers will give cannabis or a placebo to 40 people with HIV to see if it changes how their drugs work. The goal is to understand if canna…

This study asks people who have taken part in HIV clinical trials to give permission for their stored blood and tissue samples to be used in future research, including genetic testing. The goal is to have a large collection of samples ready for studies that haven't been planned y…

This pilot study tests whether an electronic health record tool can help doctors identify patients at higher risk for HIV and prescribe PrEP, a daily pill that prevents HIV. Researchers will roll out the tool in 2-3 community health centers and compare PrEP prescription rates to …

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…

This study looks at 180 women in India with cervical cancer who are receiving standard chemoradiation. Half are HIV-positive and half are HIV-negative. Researchers want to see if HIV affects how often patients complete treatment and how severe side effects are. The goal is to lea…

This study planned to test whether changing the layout and systems of HIV clinics in Uganda could make them feel more private and welcoming, reducing stigma and improving patient retention. Researchers intended to survey patients and staff before and after renovations. However, t…

This study follows 830 women in Alabama who are at risk for HIV and sexually transmitted infections (STIs). Researchers will use a smartphone app to provide information and resources, and track how many women start using PrEP, a medication that prevents HIV. The goal is to learn …

This study follows over 3,000 Black people with HIV in the UK to understand how genes and lifestyle affect their risk for kidney disease, heart disease, diabetes, and obesity. Researchers collect health data and blood/urine samples to find genetic markers that predict these condi…

This study examines how the COVID-19 pandemic affected syphilis cases and their interaction with HIV. Researchers will review medical records of 240 adults diagnosed with syphilis in Italy between 2017 and 2025. The goal is to see if pandemic restrictions led to delayed diagnoses…